VANCOUVER, British Columbia, Jan. 7, 2011 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the 4th Annual OneMedForum Emerging Company Finance Conference on Wednesday, January 12 at 8:10 AM PST. The conference is being held at the Sir Francis Drake Hotel in San Francisco.
Dr. Rewcastle will provide an overview of Enox's technology and its ability to embed nitric oxide into polymer based medical devices rendering them antimicrobial. He will also present the multibillion dollar market potential of this technology.
"I anticipate a very positive response from our presentation at OneMedForum," said Rewcastle. "This conference is attended principally by CEOs and Investors. The Enox story is attractive to both these audiences from a licensing and investment prospective, respectively."About Enox Biopharma, Inc.
Enox Biopharma, Inc. is an emerging biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymer or silicone based medical devices. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes, tympanostomy tubes and cosmetic implants. With the current CMS non-coverage of nosocomial infections the financial burden of infections has shifted to hospitals who are desperately seeking ways to reduce infection rates. By utilizing NO, part of the human body's innate immune system, Enox Biopharma is improving existing medical devices by making them antimicrobial.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's good faith views and expectations when made. Forward-looking statements are inherently subject to known and unknown risks and uncertainties which, in the case of the company, include raising adequate capital to continue operations, technology and product development uncertainties, and competition. Actual financial results of the company may differ, perhaps materially, from those discussed in the forward-looking statements. The company is not obligated, and does not undertake, to update its forward-looking statements or comment on the differences that may develop between its statements and actual results. Readers are encouraged to refer to the recent public filings of the company to further ascertain the risks associated with the forward-looking statements. Readers are urged not to place undue reliance upon such statements.For more information, please contact:John C. Rewcastle, Ph.D., CEO orItamar David, CFOEnox Biopharma, Inc.604.637.9744 phone888.224.7259 email@example.com
|SOURCE Enox Biopharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved